Early IVF-ET treatment was performed using natural cycles and with the development of ultra-ovulatory technology, most of the ultra-ovulatory protocols are now used with different protocols to obtain multiple eggs and embryos. The choice of an ultra-ovulatory regimen takes into account a number of factors, and the regimen and the dose of ultra-ovulatory drugs are determined by assessing the patient’s ovarian reserve. The assessment of ovarian reserve takes into account the patient’s age, baseline endocrine levels, ultrasound sinus follicle count, and newer markers this year, including inhibin and good anti-mullerian hormone. Each option has its advantages and disadvantages and the physician will choose the most appropriate option for the patient on an individual basis. Currently, the following ovulation protocols are frequently used: (1) Long protocol: A commonly used protocol for most patients with normal ovarian function, which can achieve satisfactory pregnancy rates. GnRH agonist is usually given during the luteal phase of the preceding menstrual period, either as a one-time injection of a long-acting preparation or as a daily injection of a short-acting preparation, and superovulation with gonadotropins is started from the third day of menstruation. The dose of gonadotropins is decided according to the patient’s age, weight, ovarian reserve function, etc. The dose of gonadotropins is closely monitored during superovulation, and the dose of gonadotropins is increased or decreased as needed until HCG day. (2) Short regimen: Usually used in patients with poor response and poor ovarian reserve function. May affect endometrial tolerance as it can cause a temporary increase in E2 and P levels in the early follicular phase. Short-acting GnRH agonists are usually given daily starting on day 3 of menstruation, along with gonadotropins for superovulation until HCG day. (3) Ultrashort regimen: used in patients with poor ovarian reserve. GnRH agonist and gonadotropin are given daily on day 3 of menstruation and GnRH agonist is discontinued after only 5-6 days of use. (4) Ultra-long regimen: For patients with endometriosis, 3 doses of long-acting GnRH agonist are given prior to treatment, followed by ultra-ovulation 4 weeks after the last dose. Since multiple GnRH agonists may affect ovarian function, the starting dose of gonadotropins can be increased if necessary. (5) Antagonist regimen: The currently commonly used regimen, GnRH antagonist is given from day 6 of superovulation, or when the dominant follicle reaches 14 mm, until HCG day. This approach is comfortable and convenient. Current studies surface that pregnancy rates are comparable between GnRH agonist and antagonist approaches, but it is also thought that antagonists have slightly lower pregnancy rates. The advantage is that in patients with PCOS or other ovarian hyperresponsiveness, the incidence of ovarian hyperstimulation can be significantly reduced. (6) Microstimulation regimen: clomiphene followed by HMG from day D3 of the menstrual cycle. This approach is inexpensive to administer and is a good option for patients with poor ovarian reserve function or PCOS. However, some studies suggest that frozen embryo transfer can be used because of poor endometrial tolerance due to the use of clomiphene. (7) Natural cycle protocol: Ovulation is observed around day 10 of the cycle and egg retrieval is performed when the follicles grow to a certain size depending on hormonal and other conditions.